Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Amneal Pharmaceuticals

It’s been a rough 2019 for some biotechs. Amneal Pharmaceuticals Inc (NYSE: AMRX) is down 81% year-to-date, while Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is down 41%.

Teva Vs. Amneal: JPMorgan Sees Hope For One, Decline For The Other

Teva Pharmaceutical Industries Ltd. TEVA, +0.32% was upgraded to neutral from underweight by J.P.

Teva upgraded to neutral by J.P. Morgan

First Majestic Silver

Aimmune Therapeutics

Antero Midstream Partners

Amarin Corporation Plc

Exelixis

Intercept Pharma

Innovative Industrial Properties

Lovesac Company

Livongo Health Inc

Meet Group

Ping Identity Holding Corp

Pinterest

Redfin

Stitch Fix

StoneCo

Trupanion

Big gains could be just a click of the buy button away.

20 Stocks That Could Double Your Money in 2020

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance.

Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

Teva stock fell sharply this year in large part thanks to the opioid crisis, but with a last-minute deal, shares look more interesting now.

With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2019 Results - Earnings Call Transcript

Investors grew optimistic that the company's legal and financial risks from the ongoing opioid epidemic may be coming to an end.

Here's Why Teva Pharmaceuticals Gained 18.5% in October

Teva Pharmaceutical Industries Ltd  on Thursday expressed confidence in its ability to continue paying down its huge debt burden even if it is forced to pay billions of dollars to settle thousands of U.S. opioid lawsuits.

Teva Pharm says opioid settlement will not derail ability to cut debt

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. Shares rise in pre-market trading.

Teva (TEVA) Q3 Earnings Miss, Sales Top Estimates, Stock Up

Teva Pharmaceutical Industries  nudged up its full-year earnings guidance on Thursday, after reporting a drop in third-quarter profit that broadly met expectations.

Teva Pharm nudges up earnings forecast, names new CFO

Teva Pharma earnings slightly missed Q3 views, while revenue was in line. The drug giant slightly raised full-year guidance.

Teva Pharma Earnings Miss, But Full-Year Guidance Raised

Shares of Teva Pharmaceuticals Ltd. TEVA, -5.15% were little changed in premarket trading Thursday, after the Israel-based drug maker reported third-quarter results that missed expectations, but lifted the low end of its profit and revenue guidance ranges.

Teva misses profit and revenue expectations, but lifts full-year guidance ranges

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales

What's in the Cards for Teva (TEVA) This Earnings Season?

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.15 in the latest trading session, marking a -0.49% move from the prior day.

Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know

Teva Pharmaceutical's proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review.

Teva's proposed opioid settlement could cost drugmaker pennies on the dollar

Teva Pharmaceutical Industries Ltd's proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.

Teva’s proposed opioid settlement could cost drugmaker pennies on the dollar

Johnson & Johnson

Walgreens

Don’t play the headlines and don’t make the mistake of lumping all opioid stocks together.

2 Sells and 1 Buy in Opioid Stocks

American Airlines

General Motors

These Buffett stocks have microscopic forward price-to-earnings ratios, as well as their own unique set of challenges.

The 3 Cheapest Stocks Warren Buffett Owns

The company announced an unexpectedly favorable settlement in a lawsuit related to the opioid epidemic.

Here's Why Teva Pharmaceutical Soared Today

Teva Pharmaceutical Industries Ltd. shares TEVA, +8.77% jumped 9.7% in afternoon trade Monday, after the Israeli generics company said it has reached a settlement with a group of attorneys general from North Carolina, Pennsylvania, Tennessee and Texas, along with defendants, to resolve litigation relating to opioid cases.

Teva shares jump about 10% on news of settlement with four states in opioid litigation

Teva Pharmaceutical shares surged after announcing a settlement that would resolve allegations that it helped fuel the nation’s opioid crisis.

Teva Pharmaceutical shares surge after announcing global opioid settlement

AmerisourceBergen

Cardinal Health

McKesson

The first federal trial on the opioid crisis in the United States has been scrapped, after the court agreed to a $260m (£200m) settlement by the country's three largest drug distributors.

US drug giants settle first federal opioids lawsuit for $260m

Four drug companies plan to announce settlements Monday ahead of a massive trial that would accuse them of helping to fuel the nation's crippling opioid crisis, according to a report.

Drug Firms Reportedly Ink Last-Minute Deal Ahead Of Ohio Opioid Trial

CLEVELAND – Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Four drug companies reach legal settlement for role in opioid addiction epidemic

But drug companies still have thousands of other opioid cases to contend with.

News for Teva Pharmaceutical Stock (TEVA)